Denali, Takeda scrap PhI Alzheimer's drug due to safety signals, 'rapidly evolving' landscape

As Biogen takes a preclinical Denali compound targeting amyloid beta forward in Alzheimer’s, Denali is shelving another Alzheimer’s candidate that is partnered with Takeda and hits a different target.

Phase I data suggest that the drug, known as TAK-920 or DNL919, has a “narrow therapeutic window” given safety signals, Denali said. Together with Takeda, it now plans to go back to the drawing board, focusing on backup molecules still in the preclinical stage, including potential combinations.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。